Grant: Travel Awards - Institute Community Support
Research Institute of the McGill University Health Centre
$2,475.00
Impact of Eliminating a Structural Barrier: Removing Fibrosis Stage Restrictions on HCV Treatment Uptake
FY 2018-19
Summary
Cures for Hepatitis C (HCV) now exist. Clinical guidelines recommend treatment for everyone. However, because of high costs, treatments have been reserved for people with the most damaged livers (known as significant liver fibrosis). This may prevent younger, more vulnerable people from accessing treatment.
Different provinces in Canada removed the need to have significant liver fibrosis as a criterion at different times, and this creates what is known as a natural experiment. Using this natural experiment and data from a large cohort study of people living with HIV and HCV, we evaluated the impact of this policy change.
We found removing the need for significant liver fibrosis, increased treatment initiations by two times and expanded access to more vulnerable population such as, people who inject drugs. Worldwide, countries will have to minimize limitations so that more people will access treatments.
Department
Program
Travel Awards - Institute Community Support
Location
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
391346
Name
Saeed Sahar Z
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
HIV/AIDS and/or other Sexually Transmitted and Blood-borne Infections (STBBIs).
Projecttitle
Impact of Eliminating a Structural Barrier: Removing Fibrosis Stage Restrictions on HCV Treatment Uptake
Programtype2
Undefined
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$2,475
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Co-Infection; Difference-In-Differences; Direct Acting Antivirals; Hepatitis C; Hiv; Ics Travel Awards; Natural Experiment; People Who Inject Drugs; Vulnerable Populations
Abstract
Cures for Hepatitis C (HCV) now exist. Clinical guidelines recommend treatment for everyone. However, because of high costs, treatments have been reserved for people with the most damaged livers (known as significant liver fibrosis). This may prevent younger, more vulnerable people from accessing treatment.
Different provinces in Canada removed the need to have significant liver fibrosis as a criterion at different times, and this creates what is known as a natural experiment. Using this natural experiment and data from a large cohort study of people living with HIV and HCV, we evaluated the impact of this policy change.
We found removing the need for significant liver fibrosis, increased treatment initiations by two times and expanded access to more vulnerable population such as, people who inject drugs. Worldwide, countries will have to minimize limitations so that more people will access treatments.
Competitiondate
201808
Approvedterm2
1 yr 0 mth
Pinamesdelim
Saeed, Sahar Z
Approvedterm
1 an 0 mois
Cihrcontribution2
HIV/AIDS~ $2,475~ $0~
